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controlled clinical trials are warranted to establish the
best possible treatment option for patients with treat-
ment failure to adefovir.
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Pathogenesis of primary sclerosing cholangitis
To the Editor:
We read with great interest the excellent review by
Weismuller et al. [1], recently published in the Journal,
regarding the pathogenesis and management of pri-
mary sclerosing cholangitis (PSC). Although PSC has
been considered an autoimmune disease, because auto-
antibodies are detected frequently, there is neither
consistent nor favorable response to immunosuppres-
sive therapy.
However, as the authors emphasized [1], some exper-
imental studies have supported the hypothesis of an
enterohepatic circulation of long-lived lymphocytes,
which are generated in the gut and translocated to the
liver [2]. This could explain the high frequency of
inﬂammatory bowel disease (IBD) in PSC patients and
why PSC may develop many years after colectomy.
We would like to draw attention to the results of our re-
cently published study [3], which add to and support this
hypothesis(1). In this study [3], we evaluated 53 patients
who underwent liver transplantation (LT) for PSC and
found that after a median time of 60 months after trans-
plantation, 7 of these patients had recurrence of PSC
(rPSC) in the liver graft, based on biochemical, histolog-
ical and radiological ﬁndings. Interestingly, all 7 pa-
tients had ulcerative colitis (UC) and none of them
had undergone total colectomy before LT. In addition,
rPSC did not develop in any of the PSC patients without
UC before or after LT (n = 14), nor in those with pre-
LT total colectomy (n = 6). Thus, it seems that the ab-
sence of UC after LT (due to pre-LT colectomy or
not) is an important factor preventing rPSC. In the uni-
variate analysis, the 7 patients with rPSC, compared to
the 46 without rPSC, had more frequent admissions to
hospital for exacerbations of UC prior to LT, and like-
lihood of having UC (de novo or not) after LT. In addi-
tion, the patients who developed rPSC had more active
UC post-LT as reﬂected by the need for maintenance
steroids given for beyond 3 months from LT. In fact,
the latter parameter was the only variable independently
associated with rPSC. Thus, the development of rPSC
was associated with several factors, all related to the
presence or activity of UC before or after LT. Our study
[3] is the ﬁrst, in which immunosuppressive therapy,
activity of UC and impact of de novo UC after LT were
evaluated in the same cohort.
Our ﬁndings are in keeping with a previous study in
which factors associated with UC were also associated
with rPSC. Vera et al. [4] reported that male gender
and an intact colon post-LT were the strongest predic-
tors of rPSC, and the use of maintenance steroids had
a univariate association. However, it was not stated if
the absence of UC before LT and/or de novo UC post-
LT were associated with rPSC, and the severity of
UC was not found to be associated with rPSC [3]. How-
ever, Graziadei et al. [5] only found a non signiﬁcant
association between the presence of UC and rPSC, but
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data concerning the severity of UC, de novo UC, or the
impact of colectomy were not evaluated. Kugelmas et al.
[6] only found a trend between maintenance steroids and
rPSC, but they only evaluated the presence or absence of
UC.
In conclusion, the course of our cohort transplanted
for PSC does support the hypothesis that the gut is
the source of lymphocytes or their products that then
set up an inﬂammatory process in which bile ducts are
damaged leading to (recurrent) PSC. This group of
transplanted patients with PSC could provide a basis
for study to elucidate the pathogenesis of PSC in non
transplanted patients.
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Recurrence of primary sclerosing cholangitis after liver
transplantation – A model for pathogenesis?
To the Editor:
We appreciate the important comment from Cholong-
itas et al. regarding our recently published article [1]
which discusses the pathogenesis of primary sclerosing
cholangitis (PSC). The comment points out that the iden-
tiﬁcation of risk factors for the recurrence of PSC after
liver transplantation (OLT) may help to understand
pathogenetic mechanisms of this enigmatic disease.
However, the issue of recurrent PSC (rPSC) following
OLT has always been controversial, because there are a
number of possible pathogenetic mechanisms resulting
in a phenotype of sclerosing cholangitis in the liver allo-
graft that resemble PSC [2]. These include chronic duc-
topenic rejection as well as biliary complications such as
anastomotic or non-anastomotic strictures. The latter
can be caused by hepatic artery thrombosis or stenosis,
but are also frequently seen without an obvious impaired
arterial perfusion, and have therefore been designated
ischemic-type biliary lesions (ITBL) [3]. Several retro-
spective studies have found a greater frequency of biliary
strictures in patients who were transplanted for PSC in
comparison to patients receiving a liver transplantation
for other end-stage liver diseases [2]. It can be assumed
that these additional bile duct changes in the allograft fol-
lowing OLT for PSC are due to the recurrence of the dis-
ease. Thus, in cases of a typical cholangiographic or
histological picture following OLT for PSC, rPSC should
be diagnosedonly after the exclusion of accepted causes of
sclerosing cholangitis (which include hepatic artery
thrombosis/stenosis, ABO incompatibility, and chronic
ductopenic rejection). While anastomotic strictures alone
are clearly related to the transplantation procedure itself,
the diﬀerentiation between ITBL and rPSC remains diﬃ-
cult. The widely accepted criteria for PSC recurrence pub-
lished by the Mayo group [2] assume that – unless
otherwise explainable – biliary strictures in the cholangi-
ogram, or a ﬁbrous cholangitis detected in a liver biopsy
specimen after more than 90 days following OLT for
PSC are deemed to represent rPSC. However, this 90
day rule is questionable since a considerable number of
ITBL are diagnosed more than 3 months after OLT;
according to one study [4] 40% of intrahepatic strictures
were seen more than 6 months after OLT.
In the accurate study of Cholongitas et al. [5] strict
inclusion and exclusion criteria for rPSC as deﬁnded by
the Mayo Clinic were used, based on detailed clinical
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